Friday, April 27, 2018
astraia supports STATIN trial in cooperation with the Fetal Medicine Foundation, London
We are proud to announce that astraia is supporting the STATIN trial in cooperation with the Fetal Medicine Foundation (FMF), London. The STATIN trial is a double-blind randomised placebo-controlled trial and aims to examine if the prophylactic use of pravastatin from 35-37 weeks’ gestation in woman at increased risk for PE can reduce the incidence and severity of the disease. The trial is powered for a 50% reduction in incidence of term-PE from 12% in the placebo group to 6% in the pravastatin group. For a power of 90%, using a two sided test at the 5% level of significance, it is necessary to randomise 1,020 high-risk pregnancies. For more details please visit https://fetalmedicine.org/research/new-randomized-trials.
astraia supports the study trial by providing a specific screen for participating study centres in Spain, Italy, Belgium, Romania and the UK so they can easily document the examination results during their normal clinical workflow and – after the trial ends – easily evaluate and bring together the results from all participating study centres.